Keymed Biosciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bo Chen
Chief executive officer
CN¥4.8m
Total compensation
| CEO salary percentage | 95.9% |
| CEO tenure | 3.7yrs |
| CEO ownership | n/a |
| Management average tenure | 4.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Health Check: How Prudently Does Keymed Biosciences (HKG:2162) Use Debt?
Oct 21
There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump
May 13News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat
Apr 03Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 31A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)
Nov 13Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts
Sep 03Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher
Mar 21Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth
Jun 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -CN¥743m |
| Mar 31 2024 | n/a | n/a | -CN¥551m |
| Dec 31 2023 | CN¥5m | CN¥5m | -CN¥359m |
| Sep 30 2023 | n/a | n/a | -CN¥313m |
| Jun 30 2023 | n/a | n/a | -CN¥267m |
| Mar 31 2023 | n/a | n/a | -CN¥287m |
| Dec 31 2022 | CN¥4m | CN¥4m | -CN¥308m |
| Sep 30 2022 | n/a | n/a | -CN¥281m |
| Jun 30 2022 | n/a | n/a | -CN¥253m |
| Mar 31 2022 | n/a | n/a | -CN¥2b |
| Dec 31 2021 | CN¥4m | CN¥4m | -CN¥4b |
| Sep 30 2021 | n/a | n/a | -CN¥4b |
| Jun 30 2021 | n/a | n/a | -CN¥4b |
| Mar 31 2021 | n/a | n/a | -CN¥3b |
| Dec 31 2020 | CN¥231k | CN¥227k | -CN¥819m |
| Dec 31 2019 | CN¥188k | CN¥183k | -CN¥168m |
Compensation vs Market: Bo's total compensation ($USD656.03K) is above average for companies of similar size in the Hong Kong market ($USD481.95K).
Compensation vs Earnings: Bo's compensation has increased whilst the company is unprofitable.
CEO
Bo Chen (49 yo)
3.7yrs
Tenure
CN¥4,788,000
Compensation
Dr. Bo Chen has been executive Director, chairman of Board and chief executive officer at Keymed Biosciences Inc. since April 03, 2021 and served as Director since April 23, 2018 until April 03, 2021. Dr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 3.7yrs | CN¥4.79m | no data | |
| Senior VP & Executive Director | 3.7yrs | CN¥1.61m | no data | |
| Senior VP & Executive Director | 6.6yrs | CN¥2.81m | no data | |
| Senior VP & Non Executive Director | 6.8yrs | CN¥178.00k | no data | |
| CFO, VP & Joint Company Secretary | 4.3yrs | no data | no data | |
| Senior Vice President | 6.8yrs | no data | no data | |
| Joint Company Secretary | 2.8yrs | no data | no data |
4.3yrs
Average Tenure
49yo
Average Age
Experienced Management: 2162's management team is considered experienced (4.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 6.7yrs | CN¥4.79m | no data | |
| Senior VP & Executive Director | 6.5yrs | CN¥1.61m | no data | |
| Senior VP & Executive Director | 3.8yrs | CN¥2.81m | no data | |
| Senior VP & Non Executive Director | 6.5yrs | CN¥178.00k | no data | |
| Independent Non Executive Director | 3.7yrs | CN¥572.00k | no data | |
| Independent Non Executive Director | 3.7yrs | CN¥476.00k | no data | |
| Independent Non-Executive Director | 3.7yrs | CN¥476.00k | no data | |
| Non Executive Director | 3.8yrs | no data | no data | |
| Non Executive Director | 3.8yrs | no data | no data |
3.8yrs
Average Tenure
49yo
Average Age
Experienced Board: 2162's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 02:48 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Keymed Biosciences Inc. is covered by 19 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Wangbin Zhou | China International Capital Corporation Limited |